Viewing data from:

TRI-LO-ESTARYLLA

ANDA

ETHINYL ESTRADIOL; NORGESTIMATE | A091232 | XIROMED PHARMA ESPANA SL

1 strength0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$0.1049

per ea

Lowest NADAC/Unit

$0.1049

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
70700012085TRI-LO-ESTARYLLA TABLET	$0.1049	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 1 NDC (1 FSS)

Lowest Price

$19.32

Highest Price

$19.32

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
42291-0565-84ETHINYL ESTRADIOL 0.025MG/NORGESTIMATE TRIPHA	$19.32	FSS	AvKare, LLC	06/14/2028

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Tri-Lo-Estarylla (2024)

Total Spending

$59K

Total Claims

2,654

Beneficiaries

590

Avg Cost/Unit

$0.55

Spending Trend

$34K(2019)→$52K(2020)→$64K(2021)→$60K(2022)→$55K(2023)→$59K(2024)

YoY Change:-17.9%

5yr CAGR:-8.7%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

Products (1)

#001 — 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG

0 patents0 exclusivities▴

TABLET;ORAL-28 | Approved: Jun 29, 2015

No patent or exclusivity listings for this strength.